Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180779 | 0.79 | CA1 (0.39) | CA1CA2ENPP1 | |
| SCHEMBL9991336 | 0.77 | — | — | |
| SCHEMBL31478123 | 0.76 | CA1 (0.46) | CA1CA2ENPP1 | |
| SCHEMBL15461408 | 0.74 | CYP2D6 (0.35) | — | |
| SCHEMBL1025135 | 0.72 | CA1 (0.48) | CA1CA2 | |
| SCHEMBL21341537 | 0.70 | EPHX2 (0.32) | — | |
| SCHEMBL21341751 | 0.69 | — | — | |
| SCHEMBL18855680 | 0.69 | — | — | |
| SCHEMBL21798291 | 0.68 | — | — | |
| SCHEMBL31535525 | 0.67 | CA1 (0.42) | CA1CA2CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| EP-3747875-B1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021018012-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | 珠海宇繁生物科技有限责任公司 | 2021-02-04 | — | — | WO | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2791108-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-20130317000-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177224-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | GENENTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| WO-2013088315-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088315-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317000-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | CA1 2456/4885CA2 1660/4885CA4 1497/4885 |
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | IDO1, IDO2, TPH1 | CA1 2105/4885CA2 2699/4885CA4 2592/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | CA1 4435/4885CA2 1918/4885CA4 2834/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CA1 4393/4885CA2 1947/4885CA4 2874/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | CA1 4435/4885CA2 1918/4885CA4 2834/4885 |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | CA1 2456/4885CA2 1660/4885CA4 1497/4885 |
| US-20140315879-A1 | Sulfonamide Derivatives | SCN7A, SCN1B, SCN1A | CA1 1202/4885CA2 282/4885CA4 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.